<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883051</url>
  </required_header>
  <id_info>
    <org_study_id>16892</org_study_id>
    <secondary_id>H8H-CD-LAHO</secondary_id>
    <secondary_id>2008-005010-43</secondary_id>
    <secondary_id>COL MIG-202</secondary_id>
    <nct_id>NCT00883051</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment</brief_title>
  <official_title>A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CoLucid Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of
      COL-144 in treating migraine headache, in order to select a dose or doses for further
      evaluation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Migraine is a common chronic neurological disorder characterized by recurrent disabling
      episodes of moderate to severe headache accompanied by nausea, vomiting, photophobia, and
      phonophobia. Acute pharmacologic therapy for migraine aims to terminate the attack or reduce
      its severity., Analgesics are commonly used or, if these are ineffective, triptans. Since
      triptans are contraindicated in patients with coronary artery disease, uncontrolled
      hypertension, and cerebrovascular disease alternative medications are required for patients
      where simple analgesics do not work. COL-144 has no vasoconstrictor activity at clinically
      relevant concentrations and might meet this need. COL-144 was effective when given
      intravenously in a placebo-controlled dose-ranging study. This study investigates which dose
      of oral COL-144 is effective in the in acute treatment of migraine headache.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache response, defined as a reduction in headache severity from moderate or severe at baseline to mild or no headache two hours after intake of study drug.</measure>
    <time_frame>Two hours after intake of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache free (absence of headache)</measure>
    <time_frame>Two hours after intake of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache severity (4 point scale: none, mild, moderate, severe)</measure>
    <time_frame>From time immediately before intake of study drug until 2 hours after after intake of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache recurrence</measure>
    <time_frame>Within 24 hours hours after after intake of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of nausea, phonophobia, photophobia, vomiting</measure>
    <time_frame>From time immediately before intake of study drug until 2 hours after intake of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability (4 point scale: not at all, mild interference, marked interference, completely - needs bed rest)</measure>
    <time_frame>From time immediately before intake of study drug until 2 hours after intake of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for rescue medication (yes or no)</measure>
    <time_frame>Between 2 and 24 hours after intake of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression (7 point scale)</measure>
    <time_frame>Between 2 hours after intake of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to headache relief and time to pain free</measure>
    <time_frame>Within 24 hours after intake of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (spontaneously reported)</measure>
    <time_frame>Throughout the whole study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead electrocardiograms (ECGs)</measure>
    <time_frame>Baseline and within 14 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Baseline and within 14 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory parameters</measure>
    <time_frame>Baseline and within 14 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Baseline and within 14 days after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COL-144 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COL-144 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COL-144 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COL-144 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COL-144</intervention_name>
    <description>Oral application of one dose of either COL-144 50 mg, COL-144 100 mg, COL-144 200 mg, COL-144 400 mg or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with migraine with or without aura fulfilling the IHS diagnostic criteria 1.1
             and 1.2.1 (2004)

          -  History of migraine of at least 1 year

          -  Migraine onset before the age of 50 years

          -  History of 1 - 8 migraine attacks per month

          -  Male or female patients aged 18 to 65 years

          -  Female patients of child-bearing potential must be using a highly effective form of
             contraception (e.g., combined oral contraceptive, IUD, abstinence, vasectomized
             partner)

          -  Able and willing to give written informed consent

          -  Able and willing to complete a migraine diary card to record details of the attack
             treated with study medication

        Exclusion Criteria:

          -  History of life threatening or intolerable adverse reaction to any triptan

          -  Use of prescription migraine prophylactic drugs within 15 days (30 days for
             flunarizine) prior to Screening Visit and during study participation

          -  Using herbal preparations (e.g., feverfew, butterbur) for migraine prophylaxis

          -  Using 5-HT reuptake inhibitors

          -  Using drugs known to inhibit CYP450 enzymes (see Appendix 2 for details)

          -  Pregnant or breast-feeding women

          -  Women of child-bearing potential not using highly effective contraception

          -  History or evidence of coronary artery disease, ischemic or hemorrhagic stroke,
             epilepsy or any other condition placing the patient at increased risk of seizures

          -  History of hypertension (controlled or uncontrolled)

          -  History of orthostatic hypotension

          -  Current use of hemodynamically active cardiovascular drugs

          -  History within the previous 3 years or current evidence of abuse of any drug,
             prescription or illicit, or alcohol

          -  Significant renal or hepatic impairment

          -  Previous participation in this clinical trial

          -  Participation in any clinical trial of an experimental drug or device in the previous
             30 days

          -  Any medical condition or laboratory test which in the judgment of the investigator
             makes the patient unsuitable for the study

          -  Known Hepatitis B or C or HIV infection

          -  Patients who are employees of the sponsor

          -  Relatives of, or staff directly reporting to, the investigator

          -  Patients with known hypersensitivity to COL-144, other 5HT1F receptor agonists or to
             any excipient of COL-144 drug product

          -  Patients who were treated with study medication in the COL MIG-201 study (Patients
             screened but not treated under that protocol are not excluded)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Montegnee</city>
        <state>Liege</state>
        <zip>4420</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <state>Etelä-Suomi</state>
        <zip>00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyvinkää</city>
        <state>Etelä-Suomi</state>
        <zip>05850</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mikkeli</city>
        <state>Itä-Suomen Lääni</state>
        <zip>50100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pori</city>
        <state>Länsi-Suomen</state>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jyväskylä</city>
        <state>Länsi-Suomi</state>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <state>Länsi-Suomi</state>
        <zip>33200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <state>Länsi-Suomi</state>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59 037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <state>Seine-Maritime</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg/Breisgau</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göppingen</city>
        <state>Baden-Württemberg</state>
        <zip>73033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erkelenz</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41812</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itzehoe</city>
        <state>Schleswig-Holstein</state>
        <zip>25524</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bremen</city>
        <zip>28329</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gandia</city>
        <state>Comunidad Valenciana</state>
        <zip>46701</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <state>Comunidade Autónoma De Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <state>Nafarroako Foru Komunitatea</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <state>Principado De Asturias</state>
        <zip>33007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2009</study_first_submitted>
  <study_first_submitted_qc>April 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2009</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COL-144</keyword>
  <keyword>acute treatment</keyword>
  <keyword>migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

